COVID-19 vaccines

E123479
medical intervention pharmaceutical product vaccine class

COVID-19 vaccines are immunizations developed to protect against the SARS-CoV-2 virus, significantly reducing the risk of severe illness, hospitalization, and death from COVID-19.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (5)

Label Occurrences
COVID-19 vaccine 2
COVID-19 1
COVID-19 vaccines canonical 1

Statements (54)

Predicate Object
instanceOf medical intervention ⓘ
pharmaceutical product ⓘ
vaccine class ⓘ
administeredBy intramuscular injection ⓘ
commonSideEffect chills ⓘ
fatigue ⓘ
fever ⓘ
headache ⓘ
injection site pain ⓘ
muscle pain ⓘ
contributesTo herd immunity against COVID-19 ⓘ
developedDuring COVID-19 pandemic ⓘ
effectOnTransmission reduction of SARS-CoV-2 transmission risk ⓘ
effectOnVariants reduced effectiveness against some variants compared with ancestral strain ⓘ
firstWidespreadUse 2020 ⓘ
globalDistribution administered in most countries worldwide ⓘ
hasType DNA vaccine ⓘ
inactivated virus vaccine ⓘ
mRNA vaccine ⓘ
protein subunit vaccine ⓘ
viral vector vaccine ⓘ
virus-like particle vaccine ⓘ
indication prevention of COVID-19-related death ⓘ
prevention of COVID-19-related hospitalization ⓘ
prevention of severe COVID-19 ⓘ
prevention of symptomatic COVID-19 ⓘ
mechanismOfAction induction of adaptive immune response ⓘ
stimulation of T-cell response against SARS-CoV-2 ⓘ
stimulation of antibody production against SARS-CoV-2 ⓘ
publicHealthRole key tool in COVID-19 pandemic control ⓘ
purpose prevention of COVID-19 infection ⓘ
reduction of COVID-19 hospitalization ⓘ
reduction of COVID-19 mortality ⓘ
reduction of severe COVID-19 ⓘ
rareAdverseEvent anaphylaxis ⓘ
myocarditis ⓘ
pericarditis ⓘ
thrombosis with thrombocytopenia syndrome ⓘ
recommendedBy European Centre for Disease Prevention and Control ⓘ
Centers for Disease Control and Prevention ⓘ
surface form: U.S. Centers for Disease Control and Prevention

World Health Organization ⓘ
regulatoryApproval Conditional Marketing Authorization by European Medicines Agency ⓘ
Emergency Use Authorization by U.S. FDA ⓘ
Emergency Use Listing by WHO ⓘ
storageRequirement refrigeration for many products ⓘ
ultra-cold chain for some mRNA vaccines ⓘ
subjectOf large-scale clinical trials ⓘ
post-marketing safety surveillance ⓘ
targetDisease COVID-19 pandemic ⓘ
surface form: COVID-19
targetPathogen SARS-CoV-2 ⓘ
typicalSchedule primary series plus booster doses ⓘ
single-dose primary series for some products ⓘ
two-dose primary series for many products ⓘ
updatedFormulation variant-adapted vaccine ⓘ

Referenced by (6)

Full triples — surface form annotated when it differs from this entity's canonical label.

Vaccine Education Center → hasTopic → COVID-19 vaccines ⓘ
Janssen COVID-19 Vaccine → targetDisease → COVID-19 vaccines ⓘ
this entity surface form: COVID-19
Janssen COVID-19 Vaccine → targetVirus → COVID-19 vaccines ⓘ
this entity surface form: SARS-CoV-2
COVID-19 pandemic → hasVaccine → COVID-19 vaccines ⓘ
this entity surface form: mRNA COVID-19 vaccines
SARS-CoV-2 → preventedBy → COVID-19 vaccines ⓘ
this entity surface form: COVID-19 vaccine
Moderna → receivedAuthorizationFor → COVID-19 vaccines ⓘ
this entity surface form: COVID-19 vaccine